Amd Age-Related Macular Degeneration

LumiThera Inc., which provides photobiomodulation treatment for ocular damage and disease, completed its acquisition of visual electrophysiology medical device manufacturer Diopsys Inc.

Intravitreal pegcetacoplan significantly reduced geographic atrophy progression in patients with age-related macular degeneration, according to a study published in the American Journal of Ophthalmology.

Cataract surgery improved visual acuity for patients with intermediate age-related macular degeneration and neovascular AMD, according to a study published in the Canadian Journal of Ophthalmology.

Anti-VEGF regimens that include aflibercept, brolucizumab and ranibizumab were ideal in both safety and efficacy in patients with neovascular age-related macular degeneration, according to a study.

Early detection and an increased number of anti-VEGF injections, as well as accurate fluid resolution targeting during treatment induction, may improve visual outcomes for patients with neovascular age-related macular degeneration, according to a study.

In this video from the virtual American Society of Retina Specialists meeting, Carl D. Regillo, MD, discusses Archway study results of the Port Delivery System with ranibizumab (Genentech) for sustained drug delivery to treat wet AMD.

Enrollment is complete for two pivotal phase 3 studies of intravitreal pegcetacoplan, a targeted C3 therapy, for the treatment of geographic atrophy secondary to age-related macular degeneration.

The first patients have been enrolled in Notal Vision’s home-based study with its investigational OCT remote monitoring device for tracking retinal fluid in patients with wet age-related macular degeneration.

Pre-procedure anxiety is the best predictor for perceived pain during intravitreal injections and may help to identify patients at risk for elevated pain, according to a poster presentation.